Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Viatris Buys Two Eye Specialists, Setting The Stage For ‘Phase Two’ Of Its Growth Plan

Acquisitions Could Add $1bn To Net Sales By 2028

Executive Summary

The company will buy Oyster Point Pharma and Famy Life Sciences for $700m to $750m in total as management tries to move the business towards more innovation.

You may also be interested in...



Teva's New CEO Francis Takes Over A Steadier – Though Still Rocky – Organization

Teva announced the appointment of former Sandoz CEO Richard Francis as its next leader as Kare Schultz steps down.

Biocon’s $3.3bn Biosimilars Big Leap Also Marks Viatris’ 'Smart' Exit, Albeit Toehold

Biocon seals milestone deal to acquire Viatris’s biosimilars assets for up to $3.3bn, accelerating its direct commercialization push across key markets and also bringing with it rights to key in-licensed therapies, including biosimilar adalimumab, and an option to acquire the US firm’s rights for biosimilar aflibercept.

Mylan Reveals First Steps For Viatris As Key Date Approaches

Presenting its last ever financial earnings as a standalone company, Mylan revealed plans to host an Investor Day in the first quarter of next year to discuss the strategic direction of Viatris, Mylan’s proposed combination with Pfizer’s Upjohn which is due to close later this month.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC147326

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel